Summary Ten patients with small cell lung cancer were treated with high dose human lymphoblastoid interferon (50-100 megaunitsm-2) for 5 days, followed by low dose interferon (3 megaunits m-2) for 3 weeks. At the end of treatment, and one month later, there was no evidence of either complete or partial response. The treatment produced fever, anorexia and weight loss, with transient leucopenia and thrombocytopenia; there was evidence of a non-cholestatic elevation of serum alanine aminotransferase, with clinical deterioration in the condition of three patients presenting with hyponatraemia. A transient hypocalcaemia during high dose therapy was also noted. It seems that lymphoblastoid interferon as a single agent is unlikely to have a role in the treatment of small cell lung cancer, and that its administration as employed in this study is associated with considerable toxicity.
Small cell lung cancer remains a disease with a very poor prognosis in spite of recent chemotherapeutic advances (Weiss et al., 1980; Hansen, 1982) . Current results report a median survival time for intensively treated patients of around 12 months and a 2-year survival of 10-20%. Thus there is a clear need to identify new and effective agents.
The anti-tumour effect of interferon-oc has been studied in several diseases, and there have been some reports of activity in nodular lymphocytic lymphoma (Merigan et al., 1978; Gutterman et al., 1980) , breast cancer Priestman, 1980) , melanoma (Priestman, 1980; Hill et al., 1980) and myeloma (Mellstedt et al., 1979; Gutterman et al., 1980) . No activity was found in non-small cell lung cancer (Stoopler et al., 1980) , but the greater chemosensitivity of small cell lung cancer to other chemotherapeutic agents suggested the need to investigate its responsiveness to interferon. Interferon for clinical studies has usually been derived from human leucocytes (Strander, 1977) , but more recently human lymphoblastoid interferon (HLBI) has been available (Priestman, 1980) . Monoclonal antibodies may be used to purify interferon (Secher & Burke, 1980; Scott et al., 1982a) , and interferon produced by gene cloning is becoming available (Scott et al., 1982b November 1982 used have been variable, but have tended to be up to about 3 megaunits m -2. With the increasing availability of interferon, a study of high dose interferon in small cell cancer seemed appropriate (Bleehen et al., 1982) . This paper presents the detailed results of a completed study in which HLBI was administered to 10 patients. A study using human leucocyte interferon-oc in a modification of our protocol is currently in progress in Helsinki (Mattson et al., 1982) .
Materials and methods
Ten patients (7 male and 3 female) with histologically and/or cytologically proven small cell carcinoma of lung, previously untreated by radiotherapy or chemotherapy, were studied. The project received local ethical committee permission, and all patients gave informed consent. The patients were treated with human lymphoblastoid interferon (Wellcome-"Wellferon"). This highly purified interferon-a mixture is produced from the Namalwa cell line of Burkitt lymphoma. It consists of a group of proteins derived from a family of at least five structural genes for human lymphoblastoid (leucocyte type) interferon (Allen et al., 1980 megaunitsM-2-was given. As the concentration of the interferon varied between batches the amount appropriate for 12 h was made up to 20 ml with 0.9% saline-so that the infusion syringe was changed every 12h. Following the infusion, the patient was given 3 megaunits m-2 by i.m. injection, 3 x a week, commencing on Day 8, to a total of 10 injections. This resulted in the total planned duration of treatment being one month.
During the infusion, pulse, supine blood pressure and temperature were monitored every 4h, and any symptoms recorded. Haemoglobin concentration, total white cell count, platelet count, plasma electrolytes, urea and creatinine, and plasma and urinary osmolarity were measured daily for the first week, and then twice weekly (or more frequently if indicated). Liver function tests were monitored at least twice weekly, whilst circulating immune complexes and T cells were quantified at the end of the infusion and at the end of treatment. In addition, during the infusion, and for 24h following its discontinuation, serum interferon levels were estimated by means of a monoclonal antibody immunoradiometric assay (Walker et al., 1982) . Chest X-rays were performed weekly, and measurements taken to assess progression/response of disease. One 
Results
All 10 patients were in good physical condition: 9 patients were PS1, and one PS2; 6 were RS1, 3 RS2, and one RS3. Seven patients had limited disease, and 3 extensive disease. -There was no response seen during or after treatment with HLBI. Two patients failed to complete the protocol because of toxicity and these patients showed progressive disease. Of the 8 patients who showed no response during treatment, 6 showed progressive disease when reassessed one month later.
Within 1-2 h of commencing the infusion of HLBI, all patients became febrile, the pyrexia exhibiting a remittent pattern which settled towards the end of the infusion; during the i.m. therapy the patients' temperatures remained within normal limits. There was fluctuation of blood pressure during the infusion. Weakness and lethargy occurred in all patients, whilst the 2 patients who failed to complete their treatment also felt so depressed that they refused further i.m. injections. Anorexia was experienced by all patients, and during the month of treatment the mean weight (±lsd) fell from 70+20Kg to 64+17Kg (0.01 < P < 0.02 paired t test). Table. A statistically significant (P<0.001) fall in serum calcium concentration was seen at the end of the HLBI infusion, but this level, which was below the lower limit of normal, returned to pretreatment values within one week of discontinuation of the infusion.
Following commencement of the infusion, the (600-900uml-') but do not seem to cause more Days after starting H.L.B.I. severe subjective toxicities than the lower dose regimes previously described (Priestman, 1980) Serum HLBI concentrations in 10 patients when serum levels of 150uml-' were recorded. It is 2-day infusion of 50 megaunits m-2 possible that subjective toxicity varies with tely followed by 3-day infusion of 100 individual patients and does not show a direct tsM-2. relationship to dose. In one study (Rohatiner et al., 1982) using high doses of up to 200 megaunits m-2 life-threatening complications were described, and the authors have suggested that the ,els of interferon rapidly reached a plateau maximum safely tolerated daily dose should not .s maintained until the dose was increased exceed 100 megaunitsm-2 given by continuous i.v. 3rd day. This new plateau was further infusion over 7 days. We are unaware of previous d until the infusion was discontinued, reports of the exacerbation of SIADH by interferon, serum levels fell rapidly with a half life of but the fact that 3/10 patients in the present study ling the infusion dose resulted in a rise in showed clinical deterioration of their condition, concentration from around 600uml-' to with concomitant worsening of the plasma and )u ml-'. These results are shown in Figure urinary hyponatraemia. It is difficult to propose a mechanism by which interferon causes this disturbance, and an attempt to monitor the plasma ADH levels serially in the patient described in the Table failed due to technical problems in the laboratory.
Abnormalities of some liver function tests have been described with interferon, whether it is used as an antiviral or anti-inflammatory agent (Jordan et al., 1974; Greenberg et al., 1976; Kajander et al., 1979) or in the treatment of malignancy (Osserman et al., 1980; Krown et al., 1980) , with an incidence from 20-100%. Our study demonstrates that the elevated ALT values return to normal within 2 weeks, despite the continuation of treatment. It seems that the abnormality is unlikely to be dose related, or associated with cholestasis, as serum bilirubin and alkaline phosphatase showed no change.
The leucopenia may be associated with the process of margination that is known to occur with an acute inflammatory response (Robbins & Cotran, 1979 The serum levels of interferon indicate that plateau levels may be maintained satisfactorily with continuous intravenous infusions of the drug. The results in Figure 2 show that the drug is rapidly cleared from the plasma. Our studies on the serum levels in one patient following a single i.m. dose of HLBI indicated concentrations similar to values already published (Walker et al., 1982) . In those malignancies that have shown some response to interferon, there is no evidence to indicate that this is directly related to serum levels. The relationship between cell survival and human leucocyte interferon concentration in vitro has been repeated in one study using a human tumour cloning assay for several different tumours (Von Hoff et al., 1982) . Tumour from 2 patients with small cell cancer of the lung showed a reduction in colony survival at interferon concentrations of 500-1000 u ml-'-levels of the same order as those achieved in the plasma of our patients. However, a further 3 showed no significant response even at the highest drug dosage.
Despite our ability to maintain high serum levels by means of the infusion, the tumours under study failed to exhibit any response. It is possible of course that the duration of treatment was inadequate but we felt unable to continue for longer in the absence of positive response. 
